Dubodencel Drug Asset Due Diligence Report 2026

This Dubodencel Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Dubodencel can convert its Therapeutic vaccine, Dendritic cell vaccine profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Dubodencel (query alias: Dubodencel)
Modality / target	Therapeutic vaccine, Dendritic cell vaccine; Not disclosed; Immunostimulants
Highest global status	Phase 2
Originator	Diakonos Oncology Corp.
Active developers	Diakonos Oncology Corp.

The MCP disease footprint includes Glioblastoma Multiforme, Refractory Melanoma, Pancreatic Ductal Adenocarcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07288112	Phase 1/2	Recruiting	35	Primary endpoint not disclosed in English source
NCT06805305	Phase 2	Recruiting	180	Primary endpoint not disclosed in English source
NCT04552886	Phase 1	Completed	17	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Pooled analysis of phase I and expanded access study cohorts of DOC1021 (dubodencel) in combination with chemoradiation for glioblastoma.

Phase 1/2; n=25; evaluation: Positive. Reported fields: AE = Common AEs included mild, flu-like symptoms and injection-site reactions. One patient in the EAP study experienced grade 3 cerebral edema after the first DOC1021 dose that fully resolved and subsequent DOC1021 doses were completed per protocol.

540 Phase I trial of DOC1021 cell-based immunotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma | Journal for ImmunoTherapy of Cancer

Phase 1; n=7; evaluation: Positive. Reported fields: OS = [45 - 44 - 25 - 9.7 - 9.6] Month

Vaccination by homologous antigenic loading with DOC1021 as adjuvant therapy for glioblastoma: Phase I clinical trial results.

Phase 1; n=16; evaluation: Positive. Reported fields: Adverse Event: dose limiting toxicities = and there were no dose limiting toxicities ; Adverse Event: dose limiting toxicities = and there were no dose limiting toxicities

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Dubodencel addresses Glioblastoma Multiforme, Refractory Melanoma, Pancreatic Ductal Adenocarcinoma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Therapeutic vaccine, Dendritic cell vaccine—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-10-10	Cellipont Bioservices and Diakonos Oncology Corporation Collaborate to Develop Groundbreaking Therapy for Glioblastoma	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Immunogenicity durability and clinically meaningful protection
Population selection, endpoint timing, and comparator relevance
Manufacturing consistency, distribution, and uptake

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO